Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million
April 05, 2023 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Eight additional national and regional health plans are now covering ZORYVE for plaque psoriasisZORYVE is a once-daily, steroid-free cream approved for use in both adults and adolescents with plaque...
Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology
November 28, 2022 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Newly published phase 2b trial data show those treated with roflumilast cream had significantly greater improvements in itch compared to those treated with vehicle by Week 2 as assessed by the Worst...
Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report
November 21, 2022 09:15 ET
|
Arcutis Biotherapeutics, Inc.
Report highlights efforts to advance diversity and inclusion, access to medicine, sustainable business practices, and governance WESTLAKE VILLAGE, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Arcutis...
CORRECTION -- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
November 15, 2022 11:10 ET
|
Arcutis Biotherapeutics, Inc.
Study met the primary endpoint and all secondary endpointsFor the primary endpoint, 32.0% of individuals treated with roflumilast cream 0.15% achieved Investigator Global Assessment (IGA) Success...
Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
November 15, 2022 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Study met the primary endpoint and all secondary endpointsFor the primary endpoint, 32.0% of individuals treated with roflumilast cream 0.15% achieved Investigator Global Assessment (IGA) Success...
New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress
September 09, 2022 08:15 ET
|
Arcutis Biotherapeutics, Inc.
Study met its primary endpoint with 80% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59% of patients treated with vehicle...
Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.
September 07, 2022 17:00 ET
|
Arcutis Biotherapeutics, Inc.
Leverages Arcutis’ deep dermatology expertise and broad biologics experience to accelerate Ducentis’ lead compound, DS-234, in atopic dermatitisLead indication, atopic dermatitis, is a rapidly...
Arcutis Announces Second Quarter 2022 Financial Results and Provides Business Update
August 04, 2022 16:01 ET
|
Arcutis Biotherapeutics, Inc.
Received U.S. Food and Drug Administration (FDA) approval for ZORYVE™ (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis, in individuals 12 years of age...
Arcutis Biotherapeutics Announces Pricing of Public Offering of Common Stock
August 02, 2022 21:27 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing...
Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock
August 02, 2022 16:02 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing...